ByTrending Posts
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention…
Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic…
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…
Lilly’s Jaypirca Shows Strong Phase 3 Results in…
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…
Could Immix Biopharma’s Strategic Investment by Goose Capital…
Key Highlights: Strategic Investment Signals Confidence in Immix’s Mission Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharma innovator, has…
Is Novartis’ $1.4 Billion Acquisition of Tourmaline Bio…
Key Highlights A $1.4 Billion Bet on Cardiovascular Innovation Novartis announced its agreement to acquire Tourmaline Bio for…
Could GE HealthCare’s FDA-Cleared Revolution™ Vibe CT System…
Key Highlights Revolutionizing Cardiac Imaging with One-Beat ClarityGE HealthCare’s Revolution Vibe CT system has received U.S. FDA 510(k)…
Could Merck and Daiichi Sankyo’s 48% Response Rate…
Key Highlights Promising Phase 2 Data Signals Breakthrough PotentialResults from the IDeate-Lung01 trial demonstrated compelling clinical activity in…
Could Arrowhead’s $2.2B+ RNAi Collaboration with Novartis Redefine…
Key Highlights Strategic SignificanceFor Arrowhead, the deal represents its largest CNS collaboration to date, validating the TRiM™ platform’s…
Could Servier’s $450M Fragile X Acquisition Redefine Its…
Key Highlights Strategic Fit for ServierThis marks Servier’s first neurology asset acquisition, aligned with its 2030 strategy to…
Trending Posts
Latest Stories
Will GE HealthCare’s Acquisition of icometrix Redefine AI-Powered Neurology Imaging?
Chicago – GE HealthCare (Nasdaq: GEHC) announced it has entered into a definitive agreement to…
Can BD’s Expanded Recall of Alaris™ Pump Infusion Sets Trigger a Turning Point in Medical Device Safety Standards?
Key Insights BD’s updated recall follows internal testing that revealed infusion performance deviations, including flow…
Can Johnson & Johnson’s Pact with Pacira BioSciences Redefine Early Intervention for Knee Osteoarthritis?
Key Insights Expanding Non-Surgical Pathways Through this agreement, Johnson & Johnson MedTech integrates ZILRETTA® into…
Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape Europe’s Largest mRNA Patent War?
Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting…
Gallery
